{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:22:21Z","timestamp":1788960141175,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T00:00:00Z","timestamp":1601164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T00:00:00Z","timestamp":1601164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Hospital General de Mexico","award":["HGM\/DI\/08\/204\/04\/17"],"award-info":[{"award-number":["HGM\/DI\/08\/204\/04\/17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00277-020-04277-y","type":"journal-article","created":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T03:55:47Z","timestamp":1601178947000},"page":"2629-2637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of three factors (ABCB1 gene expression, steroid response, early response at day + 8) on the response to induction in patients with acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"99","author":[{"given":"Christian","family":"Ramos-Pe\u00f1afiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Olarte-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Cer\u00f3n","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"de la Cruz Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Collazo-Jaloma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Mart\u00ednez-Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,27]]},"reference":[{"issue":"19","key":"4277_CR1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-017-0516-x","volume":"10","author":"G Wei","year":"2017","unstructured":"Wei G, Wang J, Huang H, Zhao Y (2017) Novel immunotherapies for the adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol 10(19):150","journal-title":"J Hematol Oncol"},{"key":"4277_CR2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/BLCTT.S170351","volume":"8","author":"M Hefazi","year":"2018","unstructured":"Hefazi M, Litzow MR (2018) Recent advance in the biology and treatment of B cell acute lymphoblastic leukemia. Blood Lymphat Cancer 8:47\u201361","journal-title":"Blood Lymphat Cancer"},{"issue":"12","key":"4277_CR3","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ (2004) Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 101(12):2788\u20132801","journal-title":"Cancer."},{"issue":"4","key":"4277_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000492531","volume":"63","author":"N Erkut","year":"2018","unstructured":"Erkut N, Akidan O, Selim Batur D, Karabacak V, Sommez M (2018) Comparison between Hyper-CVAD anD PETHEMA ALL-93 in adult acute lymphoblastic leukemia: a single-center study. Chemotherapy. 63(4):207\u2013213","journal-title":"Chemotherapy."},{"issue":"3","key":"4277_CR5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clml.2016.11.002","volume":"17","author":"J EL-Cheikh","year":"2017","unstructured":"EL-Cheikh J, EL Dika I, Massoud R, Charafeddine M, Mahfouz R, Kharfan-Dabaja MA, Bazarbachi A (2017) Hyper-CVAD Compared with BFM-like chemotherapy for the treatment of adult acute lymphoblastic leukemia. A retrospective single-center analysis. Clin Lymphoma Myeloma Leuk 17(3):179\u2013185","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"4277_CR6","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1002\/cam4.1513","volume":"7","author":"E Crespo-Solis","year":"2018","unstructured":"Crespo-Solis E, Espinosa-Bautista K, Alvarado-Ibarra M, Rozen-Fuller E, P\u00e9rez-Rocha F, Nava-G\u00f3mez C, Ortiz-Zepeda M, \u00c1lvarez-Vera JL, Ramos-Pe\u00f1afiel CO, Meill\u00f3n-Garc\u00eda LA, Rodr\u00edguez-Rodr\u00edguez S, Pomerantz-Okon A, Turrubiates-Hern\u00e1ndez FJ, Demichelis-G\u00f3mez R (2018) Survival analysis of adult patients with ALL in Mexico City: first report from the Acute Leukemia Workgroup (ALWG) (GTLA). Cancer Med 7(6):2423\u20132433","journal-title":"Cancer Med"},{"issue":"3","key":"4277_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11899-017-0377-y","volume":"12","author":"A Kansagra","year":"2017","unstructured":"Kansagra A, Litzow M (2017) Treatment of young adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep 12(3):187\u2013196","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"4277_CR8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjh.14916","volume":"179","author":"O Wolach","year":"2017","unstructured":"Wolach O, Amitai I, De Angelo DJ (2017) Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia. Br J Haematol 179(5):705\u2013723","journal-title":"Br J Haematol"},{"issue":"3","key":"4277_CR9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.beha.2017.07.010","volume":"30","author":"N G\u00f6kbuget","year":"2017","unstructured":"G\u00f6kbuget N (2017) How sould we treat a patient relapsed Ph-negative B-ALL and what novel approaches are being investigated? Best Pract Res Clin Haematol 30(3):261\u2013274","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"4277_CR10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.beha.2017.09.007","volume":"30","author":"M Eapen","year":"2017","unstructured":"Eapen M (2017) Relapsed acute lymphoblastic leukemia: \u00bfIs it crucial to achieve molecular remission prior to trasplan? Best Pract Res Clin Haematol 30(4):317\u2013319","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"4277_CR11","doi-asserted-by":"crossref","first-page":"E2574","DOI":"10.3390\/ijms18122574","volume":"18","author":"M Prieto Vila","year":"2017","unstructured":"Prieto Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T (2017) Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci 18(12):E2574","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4277_CR12","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7(6):e577","journal-title":"Blood Cancer J"},{"issue":"8","key":"4277_CR13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1440-1754.2011.02212.x","volume":"48","author":"VA Bhadri","year":"2012","unstructured":"Bhadri VA, Trahair TN, Lock RB (2012) Glucocorticoid resistace in paediatric acute lymphoblastic leukaemia. J Paediatr Child Health 48(8):634\u2013640","journal-title":"J Paediatr Child Health"},{"issue":"3-4","key":"4277_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10428199409056282","volume":"13","author":"GJ Kaspers","year":"1994","unstructured":"Kaspers GJ, Pieters R, Klumper E, De Waal FC, Veerman AJ (1994) Glucocorticoid resistance in childhood leukemia. Leuk Lymhoma 13(3-4):187\u2013201","journal-title":"Leuk Lymhoma"},{"issue":"2","key":"4277_CR15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V100.2.420","volume":"100","author":"M Aric\u00f2","year":"2002","unstructured":"Aric\u00f2 M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, Barisone E, Poggi V, de Rossi G, Locatelli F, Micalizzi MC, Basso G, Masera G (2002) Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood. 100(2):420\u2013426","journal-title":"Blood."},{"issue":"8","key":"4277_CR16","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/leu.2011.84","volume":"25","author":"O Teuffel","year":"2011","unstructured":"Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier MC, Shah PS, Beyene J, Sung L (2011) Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 25(8):1232\u20131238","journal-title":"Leukemia."},{"issue":"3","key":"4277_CR17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G et al (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 99(3):863\u2013971","journal-title":"Blood."},{"issue":"S1","key":"4277_CR18","first-page":"S50","volume":"225","author":"A M\u00f6ricke","year":"2013","unstructured":"M\u00f6ricke A, Lauten M, Beier R, Odenwald E, Stanulla M et al (2013) Prediction of outcome by early response in childhood acute lymphoblastic leukemia. Klin Padiatr 225(S1):S50\u2013S56","journal-title":"Klin Padiatr"},{"issue":"31","key":"4277_CR19","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","volume":"27","author":"G Basso","year":"2009","unstructured":"Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G (2009) Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual diseaseon day 15 bone marrow. J Clin Oncol 27(31):5168\u20135174","journal-title":"J Clin Oncol"},{"issue":"12","key":"4277_CR20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/17425255.2016.1215423","volume":"12","author":"E Arrigoni","year":"2016","unstructured":"Arrigoni E, Galimberti S, Petrini M, Danesi R, Di Paolo A (2016) ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. Expert Opin Drug Metab Toxicol 12(12):1419\u20131432","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"4277_CR21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","volume":"43","author":"ST Pan","year":"2016","unstructured":"Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF (2016) Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol 43(8):723\u2013737","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"4277_CR22","first-page":"372","volume":"15","author":"J Gregers","year":"2015","unstructured":"Gregers J, Gr\u00e9en H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, Rosthoej S, Lausen B, Schmiegelow K, Peterson C (2015) Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharm J 15(4):372\u2013379","journal-title":"Pharm J"},{"issue":"7","key":"4277_CR23","first-page":"70","volume":"61","author":"N Montazami","year":"2015","unstructured":"Montazami N, Aghapour M, Farajnia S, Baradaran B (2015) New insights into the mechanisms of multidrug resistance in cancers. Cell Mol Biol 61(7):70\u201380","journal-title":"Cell Mol Biol"},{"issue":"9","key":"4277_CR24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4067\/S0034-98872011000900004","volume":"139","author":"C Ramos","year":"2011","unstructured":"Ramos C, Rozen E, Leon M, Mart\u00ednez A, Olarte I, Castellanos H, Monta\u00f1o E et al (2011) Results of treatment of acute lymphoblastic leukemia in two cohorts of Mexican patients. Rev Med Chil 139(9):1135\u20131142","journal-title":"Rev Med Chil"},{"issue":"1","key":"4277_CR25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clml.2016.08.013","volume":"17","author":"JC Jaime-P\u00e9rez","year":"2017","unstructured":"Jaime-P\u00e9rez JC, Jim\u00e9nez-Castillo RA, Herrera-Garza JL, Guti\u00e9rrez-Aguirre H, Marfil-Rivera LJ, G\u00f3mez-Almaguer D (2017) Survival rates of adults with acute lymphoblastic leukemia in a low-income population: a decade of experience at a single institution in Mexico. Clin Lymphoma Myeloma Leuk 17(1):60\u201368","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"4277_CR26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2014-09-551937","volume":"126","author":"NV Frey","year":"2015","unstructured":"Frey NV, Luger SM (2015) How I treat adults sith relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 126(5):589\u2013559","journal-title":"Blood."},{"issue":"4","key":"4277_CR27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","volume":"95","author":"A Oriol","year":"2010","unstructured":"Oriol A, Vives S, Hern\u00e1ndez-Rivas JM, Tormo M, Heras I, Rivas C (2010) Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 95(4):589\u2013596","journal-title":"Haematologica."},{"issue":"9","key":"4277_CR28","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Fo\u00e0 R, Bassan R, Arslan \u00d6, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Br\u00fcggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847","journal-title":"N Engl J Med"},{"issue":"11","key":"4277_CR29","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/10428194.2019.1605071","volume":"60","author":"H Rafei","year":"2019","unstructured":"Rafei H, Kantarjian HM, Jabbour EJ (2019) Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma 60(11):2606\u20132621","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"4277_CR30","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH, ECOG, MRC\/NCRI Adult Leukemia Working Party (2005) Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 106(12):3760\u20133767","journal-title":"Blood."},{"issue":"16","key":"4277_CR31","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood-2017-05-783852","volume":"130","author":"M Lafage-Pochitaloff","year":"2017","unstructured":"Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, Tigaud I, Eclache V, Delabesse E, Bilhou-Nab\u00e9ra C, Terr\u00e9 C, Chapiro E, Gachard N, Mozziconacci MJ, Ameye G, Porter S, Grardel N, B\u00e9n\u00e9 MC, Chalandon Y, Graux C, Huguet F, Lh\u00e9ritier V, Ifrah N, Dombret H, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) (2017) Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood. 130(16):1832\u20131844","journal-title":"Blood."},{"issue":"2","key":"4277_CR32","first-page":"154","volume":"87","author":"JM Ribera","year":"2002","unstructured":"Ribera JM, Ortega JJ, Oriol A, Granada I, Hern\u00e1ndez-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, Gonz\u00e1lez-Valent\u00edn ME, Moreno MJ, Besalduch J, Fern\u00e1ndez-Calvo J, Tormo M, Arias J, Molin\u00e9s A, Sanz MA, Maldonado J, Mill\u00e1 F, Feliu E, San Miguel JF, PETHEMA Group, Spanish Society of Hematology (2002) Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica. 87(2):154\u2013166","journal-title":"Haematologica."},{"issue":"3","key":"4277_CR33","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2001-12-0371","volume":"100","author":"A Tafuri","year":"2002","unstructured":"Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, Mecucci C, Tedeschi A, Fioritoni G, Ferrara F, di Raimondo F, Gallo E, Liso V, Fabbiano F, Cascavilla N, Pizzolo G, Camera A, Pane F, Lanza F, Cilloni D, Annino L, Vitale A, Vegna ML, Vignetti M, Fo\u00e0 R, Mandelli F, GIMEMA Group (2002) MDR1 protein expresi\u00f3n is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 100(3):974\u2013981","journal-title":"Blood."},{"issue":"5","key":"4277_CR34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/10245332.2016.1265780","volume":"22","author":"I Olarte Carrillo","year":"2017","unstructured":"Olarte Carrillo I, Ramos Pe\u00f1afiel C, Miranda Peralta E, Rozen Fuller E, Kassack Ipi\u00f1a JJ, Centeno CF (2017) Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia. Hematology. 22(5):286\u2013291","journal-title":"Hematology."},{"key":"4277_CR35","doi-asserted-by":"crossref","unstructured":"Boyer T, Gonzales F, Barth\u00e9l\u00e9my A, Marceau-Renault A, Peyrouze P, Guihard S et al (2019) Clinical significance of ABCB1 in acute myeloid leukemia: a comprehensive study. Cancers 11(9)","DOI":"10.3390\/cancers11091323"},{"issue":"1","key":"4277_CR36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yexmp.2011.09.004","volume":"92","author":"PS Chauhan","year":"2012","unstructured":"Chauhan PS, Bhushan B, Singh LC, Mishra AK, Saluja S, Mittal V, Gupta DK, Kapur S (2012) Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Exp Mol Pathol 92(1):44\u201349","journal-title":"Exp Mol Pathol"},{"issue":"1-2","key":"4277_CR37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.drup.2012.02.001","volume":"15","author":"BC Shaffer","year":"2012","unstructured":"Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM (2012) Drug resistance: still a daunting challenge to the successful treatment of AML. DrugResist Updat 15(1-2):62\u201369","journal-title":"DrugResist Updat"},{"issue":"1","key":"4277_CR38","first-page":"1","volume":"16","author":"JE Meg\u00edas-Vericat","year":"2016","unstructured":"Meg\u00edas-Vericat JE, Rojas L, Herrero MJ, Bos\u00f3 V, Montesinos P, Moscard\u00f3 F, Poveda JL, Sanz MA, Ali\u00f1o SF (2016) Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis. Pharm J 16(1):1\u20132","journal-title":"Pharm J"},{"issue":"4","key":"4277_CR39","first-page":"372","volume":"15","author":"J Gregers","year":"2015","unstructured":"Gregers J, Gr\u00e9en H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, Rosthoej S, Lausen B, Schmiegelow K, Peterson C (2015) Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lympholastic leukemia. Pharm J 15(4):372\u2013379","journal-title":"Pharm J"},{"issue":"4","key":"4277_CR40","first-page":"418","volume":"72","author":"T Motoji","year":"2000","unstructured":"Motoji T, Motomura S, Wang YH (2000) Multidrug resistance of acute leukemia and a strategy to overcome it. Int J Hematol 72(4):418\u2013424","journal-title":"Int J Hematol"},{"issue":"5","key":"4277_CR41","first-page":"7585","volume":"8","author":"H Zhang","year":"2015","unstructured":"Zhang H, Zhang Z, Li G (2015) Collection 2015. Polimorfismo ABCB1 y susceptibilidad a la leucemia linfobl\u00e1stica aguda: un metaan\u00e1lisis. Int J Clin Exp Med 8(5):7585\u20137591","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"4277_CR42","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","volume":"94","author":"M D\u00f6rdelmann","year":"1999","unstructured":"D\u00f6rdelmann M, Reiter A, Borkhardt A, Ludwig WD, G\u00f6tz N, Viehmann S, Gadner H, Riehm H, Schrappe M (1999) Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 94(4):1209\u20131217","journal-title":"Blood."},{"issue":"5","key":"4277_CR43","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2010.08192.x","volume":"149","author":"JL McNeer","year":"2018","unstructured":"McNeer JL, Nachman JB (2018) The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol 149(5):638\u2013652","journal-title":"Br J Haematol"},{"issue":"7","key":"4277_CR44","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3324\/haematol.2011.047613","volume":"97","author":"M Lauten","year":"2012","unstructured":"Lauten M, M\u00f6ricke A, Beier R, Zimmermann M, Stanulla M, Meissner B et al (2012) Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 97(7):1048\u20131056","journal-title":"Haematologica."},{"issue":"9","key":"4277_CR45","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B","volume":"80","author":"PS Gaynon","year":"1997","unstructured":"Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Reaman GH, Sather HN, Steinherz PG, Trigg ME, Tubergen DG, Uckun FM (1997) Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 80(9):1717\u20131726","journal-title":"Cancer."},{"issue":"8","key":"4277_CR46","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3324\/haematol.12365","volume":"93","author":"A Manabe","year":"2008","unstructured":"Manabe A, Ohara A, Hasegawa D, Koh K, Saito T, Kiyokawa N, Kikuchi A, Takahashi H, Ikuta K, Hayashi Y, Hanada R, Tsuchida M, Tokyo Children's Cancer Study Group (2008) Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children\u2019s Cancer Study Group Study L99-15. Haematologica. 93(8):1155\u20131160","journal-title":"Haematologica."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04277-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04277-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04277-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T23:25:23Z","timestamp":1632698723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04277-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,27]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4277"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04277-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,27]]},"assertion":[{"value":"20 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Hospital General de Mexico \u201cDr Eduardo Liceaga\u201d) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individuals included in the study","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}